AU2011289245B2 - Improved hematopoietic stem and progenitor cell therapy - Google Patents

Improved hematopoietic stem and progenitor cell therapy Download PDF

Info

Publication number
AU2011289245B2
AU2011289245B2 AU2011289245A AU2011289245A AU2011289245B2 AU 2011289245 B2 AU2011289245 B2 AU 2011289245B2 AU 2011289245 A AU2011289245 A AU 2011289245A AU 2011289245 A AU2011289245 A AU 2011289245A AU 2011289245 B2 AU2011289245 B2 AU 2011289245B2
Authority
AU
Australia
Prior art keywords
cells
population
hematopoietic stem
progenitor
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011289245A
Other languages
English (en)
Other versions
AU2011289245A1 (en
Inventor
Caroline Desponts
Paul Grayson
John Mendlein
Pratik Multani
David L. Robbins
Daniel Shoemaker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fate Therapeutics Inc
Original Assignee
Fate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fate Therapeutics Inc filed Critical Fate Therapeutics Inc
Publication of AU2011289245A1 publication Critical patent/AU2011289245A1/en
Application granted granted Critical
Publication of AU2011289245B2 publication Critical patent/AU2011289245B2/en
Priority to AU2015201990A priority Critical patent/AU2015201990B2/en
Priority to AU2017203597A priority patent/AU2017203597B2/en
Priority to AU2019200134A priority patent/AU2019200134B2/en
Priority to AU2021201791A priority patent/AU2021201791A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
AU2011289245A 2010-08-12 2011-08-12 Improved hematopoietic stem and progenitor cell therapy Ceased AU2011289245B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2015201990A AU2015201990B2 (en) 2010-08-12 2015-04-21 Improved hematopoietic stem and progenitor cell therapy
AU2017203597A AU2017203597B2 (en) 2010-08-12 2017-05-29 Impoved hematopoietic stem and progenitor cell therapy
AU2019200134A AU2019200134B2 (en) 2010-08-12 2019-01-10 Improved hematopoietic stem and progenitor cell therapy
AU2021201791A AU2021201791A1 (en) 2010-08-12 2021-03-23 Improved hematopoietic stem and progenitor cell therapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37321210P 2010-08-12 2010-08-12
US61/373,212 2010-08-12
PCT/US2011/047657 WO2012021845A2 (en) 2010-08-12 2011-08-12 Improved hematopoietic stem and progenitor cell therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015201990A Division AU2015201990B2 (en) 2010-08-12 2015-04-21 Improved hematopoietic stem and progenitor cell therapy

Publications (2)

Publication Number Publication Date
AU2011289245A1 AU2011289245A1 (en) 2013-03-21
AU2011289245B2 true AU2011289245B2 (en) 2015-01-22

Family

ID=45568224

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011289245A Ceased AU2011289245B2 (en) 2010-08-12 2011-08-12 Improved hematopoietic stem and progenitor cell therapy

Country Status (9)

Country Link
US (2) US20140030232A1 (enExample)
EP (2) EP3278808A1 (enExample)
JP (7) JP6047489B2 (enExample)
CN (5) CN106214701B (enExample)
AU (1) AU2011289245B2 (enExample)
BR (1) BR112013003366A2 (enExample)
CA (1) CA2807944C (enExample)
ES (1) ES2654994T3 (enExample)
WO (1) WO2012021845A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807944C (en) * 2010-08-12 2020-02-18 Fate Therapeutics, Inc. Improved hematopoietic stem and progenitor cell therapy
EP3785767A1 (en) 2011-12-02 2021-03-03 Fate Therapeutics, Inc. Enhanced stem cell composition
US10111907B2 (en) 2011-12-02 2018-10-30 Fate Therapeutics, Inc. Methods of treating ischemia
WO2014078617A1 (en) * 2012-11-16 2014-05-22 Albert Einstein College Of Medicine Of Yeshiva University Identification and use of new tumor-promoting gene in hematological malignancies
SG11201506520TA (en) * 2013-02-18 2015-09-29 Univ Health Network Methods for generating hepatocytes and cholangiocytes from pluripotent stem cells
WO2014153115A2 (en) * 2013-03-14 2014-09-25 Children's Medical Center Corporation Compositions and methods for reprogramming hematopoietic stem cell lineages
US10851412B2 (en) 2013-03-15 2020-12-01 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
CN105408472A (zh) 2013-03-15 2016-03-16 马卡斯凯尔·托莱夫·拉尔森 用于脐带血收集及细胞分离的细胞、方法和装置
RU2525143C1 (ru) * 2013-03-22 2014-08-10 Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации-Институт медико-биологических проблем Российской академии наук СПОСОБ ЭКСПАНСИИ МОНОНУКЛЕАРНЫХ КЛЕТОК ПУПОВИННОЙ КРОВИ (пкМНК) ex vivo В ПРИСУТСТВИИ МУЛЬТИПОТЕНТНЫХ СТРОМАЛЬНЫХ МЕЗЕНХИМАЛЬНЫХ КЛЕТОК (ММСК)
US20160299148A1 (en) * 2013-11-22 2016-10-13 Washington University Biomarkers for multiple myeloma
US11278572B2 (en) 2014-07-18 2022-03-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Reducing CXCR4 expression and/or function to enhance engraftment of hematopoietic stem cells
CN114058582A (zh) 2015-01-26 2022-02-18 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
WO2016123117A1 (en) * 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
WO2016164502A1 (en) * 2015-04-06 2016-10-13 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
KR20180048617A (ko) * 2015-07-20 2018-05-10 앤지오크린 바이오사이언스 인코포레이티드 줄기 세포 이식 방법 및 조성물
CA2993201A1 (en) 2015-07-21 2017-01-26 The Children's Medical Center Corporation Pd-l1 expressing hematopoietic stem cells and uses
EP3371301A4 (en) 2015-11-04 2019-06-26 Fate Therapeutics, Inc. METHOD AND COMPOSITIONS FOR INDUCING THE DIFFERENTIATION OF HEMATOPOIETIC CELLS
CN115806940A (zh) 2015-11-04 2023-03-17 菲特治疗公司 多能细胞的基因组工程改造
RU2628092C1 (ru) * 2016-02-10 2017-08-14 Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации - Институт медико-биологических проблем Российской академии наук (ГНЦ РФ - ИМБП РАН) Способ получения МСК-ассоциированных недифференцированных гемопоэтических клеток-предшественников с фенотипов CD34+/CD133+
CN105779386B (zh) * 2016-04-06 2019-09-20 南京大学 一种间充质干细胞在制备治疗m5型白血病药物中的应用
CN105886457A (zh) * 2016-05-16 2016-08-24 中国人民解放军军事医学科学院野战输血研究所 诱导干细胞分化成外胚层祖细胞的方法
WO2018073615A1 (en) * 2016-10-21 2018-04-26 Longboat Explorers Ab Methods and compositions for generating hematopoietic cells
CN106754726A (zh) * 2016-12-28 2017-05-31 溯源生命科技股份有限公司 一种提高人间充质干细胞移植和归巢效率的基因治疗方法
WO2018170046A1 (en) * 2017-03-14 2018-09-20 Orig3N, Inc. Hla-indexed repository of ipscs and ipsc-derived stem cells, and related systems and methods
WO2019060708A1 (en) 2017-09-22 2019-03-28 The Children's Medical Center Corporation TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS
EP3647413A1 (en) * 2018-10-31 2020-05-06 Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas O.A., M.P. (CIEMAT) Improvements for performing and facilitating the recovery after hematopoietic stem cell transplantation
CA3138292A1 (en) * 2019-05-17 2020-11-26 Deverra Therapeutics Inc. Compositions and methods for improving treatment outcomes for patients having hematological malignancies using an expanded stem cell product
EP3980036A4 (en) * 2019-06-06 2023-01-25 Medeor Therapeutics, Inc. Methods of making cellular products by post-mortem mobilization and harvesting of hematopoietic cells
EP3986358A4 (en) 2019-06-20 2023-06-21 Amniotics AB DEVICE FOR FILTERING FRUIT WATER
CN110585432B (zh) * 2019-08-27 2021-10-15 中国人民解放军第二军医大学 成纤维细胞生长因子受体1在制备防治肠道病毒71型感染药物中的应用
CN114765957B (zh) 2019-10-18 2025-09-12 Amniotics公司 从羊水中获得羊膜间充质干细胞的方法和设备及其来源的细胞
US20220411755A1 (en) * 2019-11-14 2022-12-29 Amgen Inc. Hematopoietic precursor cell production
JP2023543248A (ja) * 2020-09-24 2023-10-13 ▲広▼州▲輯▼因医▲療▼科技有限公司 ヒト造血幹細胞移植効率を向上させるための化合物の使用
WO2022089606A1 (en) * 2020-10-30 2022-05-05 Westlake Therapeutics (Hangzhou) Co. Limited Methods for preparing mature red blood cells in vitro
US12435308B2 (en) 2020-11-06 2025-10-07 Amniotics Ab Immunomodulation by amniotic fluid mesenchymal stem cells
WO2024040061A2 (en) * 2022-08-16 2024-02-22 The Regents Of The University Of California Alleviating graft versus host disease using engineered inkt cells
WO2024186146A1 (ko) * 2023-03-07 2024-09-12 인제대학교 산학협력단 조혈 줄기세포 증식 또는 가동화 촉진용 조성물 및 가동화 조혈 줄기세포 수집방법

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US5460964A (en) 1992-04-03 1995-10-24 Regents Of The University Of Minnesota Method for culturing hematopoietic cells
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US5709472A (en) * 1995-10-23 1998-01-20 Lifelines Technology, Inc. Time-temperature indicator device and method of manufacture
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
US5945337A (en) 1996-10-18 1999-08-31 Quality Biological, Inc. Method for culturing CD34+ cells in a serum-free medium
JP2001521753A (ja) 1997-10-31 2001-11-13 アフィメトリックス インコーポレイテッド 成人臓器及び胎児臓器中の発現プロフィール
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
WO2000038663A2 (en) 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
KR20020022798A (ko) 1999-08-13 2002-03-27 후미에 사토 프로스타글란딘 유도체
ATE327751T1 (de) 2000-01-31 2006-06-15 Pfizer Prod Inc Verwendung von aktivatoren des prostaglandinrezeptores 4 zur behandlung von akuter oder chronischer niereninsuffizienz
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
FR2825261B1 (fr) 2001-06-01 2003-09-12 Maco Pharma Sa Ligne de prelevement du sang placentaire comprenant une poche de rincage
WO2003091280A1 (en) * 2002-04-26 2003-11-06 Kirin Beer Kabushiki Kaisha Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell or hematopoietic progenitor cell, and dna coding for the same
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
US20050176140A1 (en) * 2004-02-10 2005-08-11 Benedict Daniel J. Method and apparatus for cell culture using a two liquid phase bioreactor
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
WO2006047476A2 (en) 2004-10-26 2006-05-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
DE102005062741A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Fluorene und Carbazole als Liganden des EP2 Rezeptors
EP1999255A2 (en) * 2006-03-24 2008-12-10 The Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
CN101517070A (zh) * 2006-05-31 2009-08-26 Styx有限责任公司 选择干细胞的方法及其用途
CN101506353A (zh) * 2006-06-15 2009-08-12 尼奥斯泰姆公司 外周造血干细胞的处理方法
US20110165128A1 (en) * 2008-03-07 2011-07-07 Columbia University In The City Of New York Homing in mesenchymal stem cells
EP3031907B1 (en) * 2008-11-06 2021-01-06 Indiana University Research and Technology Corporation Materials and methods to enhance hematopoietic stem cells engraftment procedures
WO2010065601A1 (en) * 2008-12-03 2010-06-10 Amorcyte, Inc. Infarct area perfusion-improving compositions and methods of vascular injury repair
JP2010193879A (ja) * 2009-01-27 2010-09-09 Jms Co Ltd 臍帯血造血幹細胞の増殖制御方法およびその用途
CA2807944C (en) * 2010-08-12 2020-02-18 Fate Therapeutics, Inc. Improved hematopoietic stem and progenitor cell therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOGGARTT, J. et al. "Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation." BLOOD, 28 May 2009. Vol. 113, No. 22. Pages 5444-5455. *
NORTH, T.E. et al. "Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis." NATURE, 21 June 2007. Vol. 447. No. 7147, pages 1007-1011. *

Also Published As

Publication number Publication date
US20140030232A1 (en) 2014-01-30
CA2807944C (en) 2020-02-18
ES2654994T3 (es) 2018-02-15
US20200339953A1 (en) 2020-10-29
JP2023109761A (ja) 2023-08-08
CN106214701A (zh) 2016-12-14
CN103167876A (zh) 2013-06-19
CN106244547A (zh) 2016-12-21
CA2807944A1 (en) 2012-02-16
JP2022009404A (ja) 2022-01-14
EP2603227B1 (en) 2017-10-04
EP2603227A2 (en) 2013-06-19
WO2012021845A3 (en) 2012-05-31
JP2018104457A (ja) 2018-07-05
CN103167876B (zh) 2016-08-31
JP2020029458A (ja) 2020-02-27
WO2012021845A2 (en) 2012-02-16
CN112501118A (zh) 2021-03-16
CN106214701B (zh) 2020-09-25
CN112516167A (zh) 2021-03-19
AU2011289245A1 (en) 2013-03-21
JP6047489B2 (ja) 2016-12-21
JP2013540105A (ja) 2013-10-31
BR112013003366A2 (pt) 2020-08-04
EP2603227A4 (en) 2014-01-15
JP6346917B2 (ja) 2018-06-20
EP3278808A1 (en) 2018-02-07
JP6574279B2 (ja) 2019-09-11
JP2018184448A (ja) 2018-11-22
CN106244547B (zh) 2021-01-01
JP2016185976A (ja) 2016-10-27

Similar Documents

Publication Publication Date Title
AU2011289245B2 (en) Improved hematopoietic stem and progenitor cell therapy
US8383404B2 (en) Hematopoietic stem cell identification and isolation
AU2019200134B2 (en) Improved hematopoietic stem and progenitor cell therapy
US20140154219A1 (en) Methods and compositions for large-scale isolation of very small embryonic-like (vsel) stem cells
Mizokami et al. Preferential expansion of human umbilical cord blood-derived CD34-positive cells on major histocompatibility complex-matched amnion-derived mesenchymal stem cells
HK1186400A (en) Improved hematopoietic stem and progenitor cell therapy
HK1186400B (en) Improved hematopoietic stem and progenitor cell therapy
HK1186387A (en) Improved hematopoietic stem and progenitor cell therapy
HK1186387B (en) Improved hematopoietic stem and progenitor cell therapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired